Companies

Zentalis Completes DENALI Enrollment, Pushes Readout to 2027

The Tip Desk · August 6, 2026 · 3 min read

Cash, cash equivalents and marketable securities stood at $174.6 million as of June 30, 2026, which the company said funds operations into late 2027.

Zentalis Pharmaceuticals (ZNTL), a clinical oncology company developing the investigational WEE1 inhibitor azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer, completed enrollment in DENALI Parts 2a and 2b and said Part 2c remains open, moving the integrated Part 2 topline readout from year-end 2026 to the first half of 2027 to allow data maturation after full enrollment.

The delay was intended to let the combined 2a, 2b and 2c dataset mature once enrollment is complete. Part 2c is designed to add about 40 patients previously treated with a taxane-containing regimen, a cohort the company added earlier in the year to keep the study population aligned with the evolving treatment landscape.

Regulatory alignment followed. After a Type D meeting with the U.S. Food and Drug Administration, the agency had no objection to continuing the selected 400 mg once-daily, five-days-on, two-days-off monotherapy dose in Cyclin E1-positive PROC, a dose chosen from a prespecified interim analysis of DENALI Part 2a. The FDA acknowledged that the DENALI Part 2 population, including 2c, has the potential to support an accelerated approval pathway, subject to the strength of the data and the landscape of approved agents at the time of regulatory action. Chief Executive Officer Julie Eastland said the accelerated approval strategy remains intact.

ASPENOVA, the Phase 3 confirmatory trial designed to support U.S. full approval and ex-U.S. registrations, had already dosed its first patient in May 2026 and is enrolling. The study is expected to enroll about 420 patients and compare azenosertib at 400 mg QD 5:2 with investigator's-choice single-agent chemotherapy, with progression-free survival as the primary endpoint.

Research and development expenses were $35.2 million for the three months ended June 30, 2026, up $7.6 million from $27.6 million a year earlier. The increase was primarily a $7.0 million milestone payment to Recurium IP Holdings tied to the start of ASPENOVA and a $5.2 million rise in clinical and manufacturing costs for DENALI and ASPENOVA, partly offset by a $4.5 million decrease in personnel expense. General and administrative expenses were $9.2 million. Total operating expenses were $44.4 million.

Net loss widened to $42.3 million, or $0.59 a share, from $26.9 million, or $0.37 a share, a year earlier. Investment and other income, net, fell to $2.2 million from $9.2 million.

Cash, cash equivalents and marketable securities were $174.6 million as of June 30, 2026, down from $211.8 million as of March 31, 2026. That balance will be sufficient to fund operating expenses and capital expenditures into late 2027. Working capital was $143.7 million and total assets were $215.3 million.

Eastland said the company remains confident that azenosertib has the potential to be an oral, non-chemotherapy option for the roughly 50% of PROC patients with Cyclin E1-positive tumors. She said Zentalis sees opportunity to expand azenosertib into platinum-sensitive ovarian cancer and additional tumor types through combinations. In May, the company named Shannon Campbell to the board and Sarah Kelly as senior vice president of commercial strategy.

ESMO accepted an abstract for a rapid oral presentation of overall survival from DENALI Part 1b and a trial-in-progress poster on ASPENOVA. At ASCO 2026, the company presented MUIR Part 1 data on azenosertib plus paclitaxel in PROC; MUIR Part 2 enrollment is ongoing for azenosertib plus bevacizumab in second-line platinum-sensitive ovarian cancer.

The next scheduled catalyst is the DENALI Part 2 integrated topline readout in the first half of 2027, after Part 2c finishes enrolling. ASPENOVA continues to enroll toward its target of about 420 patients.